1998•Chinese Journal of New Drugs and Clinical RemediesRequires access

Pravastatin vs Duo-xi-kang in treating hyperlipidemia

Chen Shou

Abstract

AIM: To compare the effects and safety of pravastatin and Duo_xi_kang in treating hyperlipidemia. METHODS: Hyperlipidemia 60 patients were randomly divided into 2 groups. Pravastatin group of 30 patients (M 16, F 14; age 58±s 11 a) received pravastatin 10_20 mg, po, qn for 6 mo. Duo_xi_kang group of 30 patients (M 18, F 12; age 60±10 a) received Duo_xi_kang 1.35 g(0.45 g/pill)po, tid for 6 mo. RESULTS: The total effective rates for reducing total cholesterol (TC), triglycerides (TG), and low_density lipoprotein cholesterol (LDL_ch) in pravastatin group were 90%, 53%, and 93%(P0.01), respectively. Duo_xi_kang did not produce marked change. There were no severe adverse reactions. CONCLUSION: Pravastatin is safe and effective on hyperlipidemia.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Pravastatin, Hyperlipidemia, Medicine, Internal medicine, Pill, Adverse effect, Gastroenterology, Cholesterol